Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6587742 | 0.98 | — | — | |
| SCHEMBL6589763 | 0.91 | — | — | |
| SCHEMBL9505606 | 0.78 | ALDH1A1 (0.40) | CXCR3SMN1; SMN2ALOX15ALDH1A1TAAR1 | |
| SCHEMBL20529724 | 0.78 | ALDH1A1 (0.41) | CXCR3SMN1; SMN2ALOX15ALDH1A1TAAR1 | |
| SCHEMBL7994890 | 0.78 | CXCR3 (0.42) | CXCR3SMN1; SMN2ALOX15ALDH1A1TAAR1 | |
| SCHEMBL7914874 | 0.78 | ALDH1A1 (0.40) | CXCR3SMN1; SMN2ALOX15ALDH1A1TAAR1 | |
| SCHEMBL20529718 | 0.78 | ALDH1A1 (0.41) | CXCR3SMN1; SMN2ALOX15ALDH1A1TAAR1 | |
| SCHEMBL9505609 | 0.78 | ALDH1A1 (0.40) | CXCR3SMN1; SMN2ALOX15ALDH1A1TAAR1 | |
| SCHEMBL7994494 | 0.78 | CXCR3 (0.42) | CXCR3SMN1; SMN2ALOX15ALDH1A1TAAR1 | |
| SCHEMBL3764950 | 0.78 | ALDH1A1 (0.40) | CXCR3SMN1; SMN2ALOX15ALDH1A1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 369 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | AZEVAN PHARMACEUTICALS, INC. (US) | 2024-04-11 | — | — | US | disclosed |
| US-20240117117-A1 | CARBOHYDRATE POLYAMINE BINDERS AND MATERIALS MADE THEREWITH | KNAUF INSULATION SPRL (BE) | 2024-04-11 | — | — | US | disclosed |
| WO-2024064209-A1 | COMPOSITIONS AND METHODS FOR TREATING MYCOBACTERIUM INFECTIONS | DATA2DISCOVERY, INC. (US) | 2024-03-28 | — | — | WO | disclosed |
| WO-2024039864-A1 | PROTEIN:PROTEIN INTERACTION INHIBITORS | PURDUE RESEARCH FOUNDATION (US) | 2024-02-22 | — | — | WO | disclosed |
| EP-4324882-A2 | BINDERS | Knauf Insulation SPRL (BE) | 2024-02-21 | — | — | EP | disclosed |
| US-20240034918-A1 | BINDERS AND ASSOCIATED PRODUCTS | KNAUF INSULATION SPRL (BE) | 2024-02-01 | — | — | US | disclosed |
| EP-3146010-B1 | BINDERS | KNAUF INSULATION INC (US) | 2023-12-13 | — | — | EP | disclosed |
| US-11814481-B2 | Carbohydrate polyamine binders and materials made therewith | KNAUF INSULATION, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| WO-2023215238-A1 | PREPARATION AND USES OF 7-AZAINDENOISOQUINOLINES | PURDUE RESEARCH FOUNDATION (US) | 2023-11-09 | — | — | WO | disclosed |
| EP-4245762-A2 | BINDERS AND ASSOCIATED PRODUCTS | Knauf Insulation SPRL (BE) | 2023-09-20 | — | — | EP | disclosed |
| WO-2012019123-A1 | PROCESSES FOR PREPARING TUBULYSINS | ENDOCYTE, INC. (US) | 2012-02-09 | — | — | WO | disclosed |
| WO-2012003436-A1 | METHODS FOR TREATING POST TRAUMATIC STRESS DISORDER | AZEVAN PHARMACEUTICALS, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| WO-2011138459-A1 | CARBOHYDRATE BINDERS AND MATERIALS MADE THEREWITH | KNAUF INSULATION (BE) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011138458-A1 | CARBOHYDRATE POLYAMINE BINDERS AND MATERIALS MADE THEREWITH | KNAUF INSULATION (BE) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011112864-A1 | PARENTERAL FORMULATIONS OF MACROLIDE ANTIBIOTICS | CEMPRA PHARMACEUTICALS, INC. (US) | 2011-09-15 | — | — | WO | disclosed |
| WO-2011109232-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL DISEASES | NOVADRUG, LLC (US) | 2011-09-09 | — | — | WO | disclosed |
| WO-2011094416-A1 | SUBSTITUTED NORINDENOISOQUINOLINES, SYNTHESES THEREOF, AND METHODS OF USE | PURDUE RESEARCH FOUNDATION (US) | 2011-08-04 | — | — | WO | disclosed |
| WO-2011085185-A1 | SOLUBLE GRAPHENE NANOSTRUCTURES AND ASSEMBLIES THEREFROM | LI LIANG-SHI (US) | 2011-07-14 | — | — | WO | disclosed |
| WO-2011032052-A1 | METHODS FOR TREATING MALARIA, TUBERCULOSIS AND MAC DISEASES | CEMPRA PHARMACEUTICALS, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
| WO-2010132494-A1 | COMPOUNDS AND METHODS FOR TREATING AIDS AND HIV INFECTIONS | GHOSH ARUN K (US) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | FABP7, PYGB, CHAT | CXCR3 1184/4885SMN1; SMN2 114/4885ALOX15 855/4885 |
| US-20240034918-A1 | BINDERS AND ASSOCIATED PRODUCTS | VCL, C1QBP, TBCB | CXCR3 3255/4885SMN1; SMN2 2143/4885ALOX15 2776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.